Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines

Anti-Cancer Drugs

Volumn 7, Issue 3, 1996, Pages 344-350

  Maki, Auday ^a,b   Mohammad, Ramzi ^a   Raza, Syed ^a   Saleh, Mohammad ^a   Govindaraju, Kanaka Durga ^a   Pettit, George R ^a   Al Katib, Ayad ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

bcl 2; c myc; Dolastatin 10; Non Hodgkin's lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; DOLASTATIN 10; ONCOPROTEIN; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NONHODGKIN LYMPHOMA; ONCOGENE C MYC; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0029942167     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199605000-00016     Document Type: Article

References (38)

1. Mohammad R, Al-Katib A, Pettit G, Sensenbrenner L. Differential effects of bryostastin-1 on human non-Hodgkin's B lymphoma cell lines. Leukemia Res 1993; 17: 1-8.
2. Nadler LM. The malignant lymphomas. In: Wilson JD, Braunwald E, Isselbacher KJ, et al. eds, Harrison's principles of Internal Medicine, 12th edn. New York: McGraw-Hill 1991; 2: 1599-612.
3. Miller PT, Dana BW, Weick JK, et al. Southwest Oncology Group clinical trials for intermediate and high grade nonHodgkins lymphomas. Semin Hematol 1988; 25: 17-25.
4. Maki AA, Diwakaran H, Mohammad R, Al-Asfar S, Pettit GR, Al-Katib A. Bcl-2 and P53 oncoproteins can be modulated by bryostatin-1 and dolastatins in human diffuse large cell lymphoma. Anti-Cancer Drugs 1995; 6: 392-7.
5. Pettit GR, Kamano Y, Herald CL, et al. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc 1987; 109: 6883-6885.
6. Bai R, Roach MC, Jayaram SK, et al. Differential effectsw of active isomers, segments and analogs of dolastatin 10 on ligand interaction with tubulin. Correlation with cytotoxicity. Biochemical Pharmacol 1993; 45: 1503-7.
7. Gray JW, Darzynkiewicz Z. Techniques in cell cycle analysis. Clinton, NJ: Humana Press 1987.
8. Arend M, Morris G, Wyllie H. Apoptosis: the role of endonuclease. Am J Pathol 1990; 136: 593-608.
9. Williams, GT. Program cell death: apoptosis and oncolgenosis. Cell 1991; 65: 1097-8.
10. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992; 11: 121-39.
11. Dive C, Evans A, Whetton D. Induction of apoptosis: new target for cancer chemotherapy. Cancer Biol 1992; 3: 417-27.
12. Wyllie H. Apoptosis and the regulation of cell numbers in normal and neoplastic tissue: an overview. Cancer Metastasis Rev 1992; 11: 95-103.
13. Tsjuimoto Y, GorhamJ, Cossman J, Jaffe E, Croce M. The t(l4,18) chromsome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985; 229: 1390-3.
14. Lowe SW, Jacks T, Housman DE, Ruley HE. Abrogation of oncogene associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sei USA 1994; 91: 2026-30.
15. McDonnel TJ, Deane N, Platt FM, et al. Bcl-2 immunoglobulin transgenic mice demonstrate extended B-cell survival and follicular lymphoproliferation. Cell 1989; 57: 79-88.
16. Bakhshi A, Jensen JP, Goldman P. Cloning the chromosomal breakpoint of t(14,18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41: 899-906.
17. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sei USA 1991; 88: 6961-5.
18. Graninger WB, Soto M, Boultain B, Goldman P, Korsmeyer SJ. Expression of bcl-2 and bcl-2 fusion transcripts in normal and neoplastic cells. J Clin Invest 1988; 80: 1512-5.
19. Amati B, Littlewood T, Evan G, Land H. The c-myc protein induce cell cycle progression and apoptosis through dimerization with max. EMBO J 1993; 12: 5083-7.
20. Bai R, Pettit GR, Hamel E. Dolastatin-10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biocbem Pharmacol 1990; 39: 1941-3.
21. Rosenberg SA, Berard CW, Brown BW Jr, et al. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of working formulation for clinical usage. Cancer 1982; 49: 2112-35.
22. Mohammad RM, Mohamed AN, Smith MR, Jawadi NS, AlKatib A. A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;ll). Cancer Genet Cytogene 1993; 70: 62-7.
23. Mohamed AN, Al-Katib A. Establishment and characterization of human lymphoma cell line (WSU-NHL) with 14,18 translocation. Leukemia Res 1988; 12: 833-43.
24. Mohamed AN, Mohammad R, Koop B, Al Katib A. Establishment and characterization of a new human Burkitt lymphoma cell line (WSU-BL). Cancer 1989; 64: 1041-48.
25. Beckwith M, Urba WJ, Longo DL. Growth inhibition of human lymphoma cell lines by the marine products, dolastatins-10 and 15. J Natl Cancer Inst 1993; 85: 483-8.
26. Al-Katib AM, Mohammad R, Maki AA, Smith MR. Induced expression of a ubiquitin C-terminal hydrolase (UCHL1) In acute lymphoblastic leukemia. Cell Growth Different 1995; 6: 211-17.
27. Li Y, Chen B. Differential regulation of fyn-associated protein tyrosin kinase activity by macrophage colonystimulating factor (M-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF). J Leukocyte Biol 1995; 57: 484-90.
28. Armitage JO, Cheson BD. Interpretation of clinical trials in diffuse large cell lymphoma. J Clin Oncol 1988; 6: 1335-9.
29. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Eng J Med 1993; 328: 1002-4.
30. Gribben JG, Freedman AS, Neuberg D. Immunologie purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Eng J Afed 1991; 325: 1525-33.
31. Bai RL, Pettit GR, Hamel E. Binding of dolastatin 10 to tubulin at a distant site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Cbem 1990; 265: 17141-9.
32. Bai RL, Pettit, GR, Hamel E. Structure activity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10. Biocbem Pharmacol 1990; 40: 1859-64.
33. Jackson DV, Bender RA. Cytotoxic thresholds of vincristin in a marine and a human leukemia cell line in vitro. Cancer Res 1979; 39: 4346-9.
34. Pezzella F, Tse AG, Cordell JL, Pulford KAF, Guter KG, Mason RY. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosome translocation. Am J Patbol 1990; 137: 225-32.
35. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80: 879-86.
36. Green DR, Bissonnette RP, Cotter TG. Apoptosis and cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Principles and practice of oncology update 8, 4th edn. 1994: 1-14.
37. Bissonnette RP, Echeverri R, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992; 359: 552-4.
38. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 1992; 359: 554-6.